This publication uses cookies

We use functional and analytical cookies to improve our website. In addition, third parties place tracking cookies to display personalised advertisements on social media. By clicking accept you consent to the placement of these cookies.

The AETBC team

Prof. Graeme Meintjes

scroll down

Recognising excellence in research and collaboration

The Tenth EDCTP Forum, held in 2021 rather than 2020 because of the COVID-19 pandemic, took place in Maputo, Mozambique, as well as virtually, attracting more than 2000 online registrants.

Every two years, EDCTP awards a number of prizes that recognise outstanding individuals and research teams from Africa and Europe who have made significant achievements in their research field. The prizes are awarded at EDCTP’s biennial Forum. After postponement of the 2020 Forum, the prizes for that year were awarded at the Tenth EDCTP Forum in October 2021. The prize winners are:

Prof. Sir Alimuddin Zumla

Prof. Margaret Gyapong

“The award of this prize from EDCTP is a highlight of my career to date. It is a recognition of the work that our research group has done.”

— Prof. Graeme Meintjes

Scientific Leadership Prize winner: Professor Graeme Meintjes

Professor Meintjes, Deputy Head of the Department of Medicine at the University of Cape Town, South Africa, has been recognised for his outstanding track record of research on the diagnosis, prevention and treatment of conditions affecting patients with advanced HIV disease in Africa, particularly HIV-associated TB, HIV-associated cryptococcal meningitis, immune reconstitution inflammatory syndrome (IRIS), the complications of antiretroviral therapy and drug-resistant TB. His EDCTP-funded projects have included landmark studies on the use of prednisone to treat and prevent TB-IRIS.

“I feel extremely humbled and honoured and to receive this very prestigious prize – especially since Dr Pascoal Mocumbi is globally distinguished and respected for his exemplar role model scientific and political work.”

— Prof. Sir Alumuddin Zumla

Outstanding Female Scientist Prize winner: Professor Margaret Gyapong, Ghana

Professor Gyapong is Director of the Institute for Health Research and Coordinator of the Centre for Health Policy and Implementation Research (CHPIR) at the University of Health and Allied Sciences, Ghana. With a background in social research, she has particular interests in socio-cultural aspects of tropical diseases, particularly neglected tropical diseases, implementation research, health systems, and maternal and child health. Under her leadership, CHPIR was designated a WHO/TDR Satellite Training Centre for Implementation Research in 2018. Among many international advisory roles, Professor Gyapong is a member of the Sight Savers Board of Trustees, the Swiss Tropical and Public Health External Review Board, and the WHO Scientific and Technical Advisory Group on Neglected Tropical Diseases.

Outstanding Research Team Prize winner: African-European Tuberculosis Consortium (AETBC)

AE-TBC is an international collaboration, encompassing seven African and five European institutions, which focuses on the development of innovative TB diagnostics based on host biomarkers. Founded in 2010 under the AE-TBC project, the consortium is continuing its work through the EDCTP-funded ScreenTB and TriageTB projects.

“I think the success of AE-TBC shows that African institutions can lead international research effectively, that long-term relationship between individuals in different institutions across the globe, and in this case across Africa, is very important.”

— Prof. Gerhard Walzl, AETBC coordinator

“You cannot say that because you are a woman, and you have these other roles to play, you are not going to strive for excellence. Hard work with excellence always pays off.”

— Prof. Margaret Gyapong

Dr Pascoal Mocumbi Prize winner: Professor Sir Alimuddin Zumla, UK

Born in Zambia, Professor Sir Alimuddin (Ali) Zumla is Professor of Infectious Diseases and International Health at University College London, UK, and a globally renowned researcher specialising in respiratory diseases, particularly TB and more recently COVID-19, and other diseases of poverty. He is a highly influential author and has worked tirelessly to strengthen collaborations between the UK, Europe and Africa, to focus world attention on diseases of poverty, and to enhance science-based health policymaking.

About the EDCTP Prizes

The biennial EDCTP Prizes recognise outstanding individuals and research teams from Africa and Europe who have made significant achievements in their research field. Additionally, the awardees will have made major contributions to strengthening clinical research capacity in Africa and supporting South-South and North-South networking.

The Prizes are part of the EDCTP programme which is supported by the European Union under Horizon 2020, it’s Framework Programme for Research & Innovation.

The road to End TB

If all stakeholders collectively and collaboratively focus on the priorities identified in this Roadmap, progress will be accelerated. The unprecedented speed at which COVID-19 vaccines have been developed holds important lessons that can be applied to TB vaccines.

One hundred years after the BCG vaccine, there is real hope that disadvantaged populations around the world can finally gain the benefits of TB prevention and cure through the use of vaccination. 

New TB vaccines will fulfil multiple roles in TB control but a stronger and more diverse TB vaccine pipeline needs to be build. It is equally important to begin preparing the ground for the introduction of new TB vaccines. An end-to-end perspective needs to be adopted. Clinical development must be informed by a sound understanding of national decision-making and implementation constraints, while licensing must be swiftly followed by efficient programmatic implementation.

Enabling factors

Global efforts are required to encourage ‘open science’ with greater sharing of data and specimens, facilitated by the establishment of biobanks and data platforms. A failure to publish data, particularly negative results, can lead to unnecessary duplication of efforts and research being carried out on approaches unlikely to be successful.

A wide range of stakeholders needs to be engaged, including global agencies, industry, regulatory authorities, national decision-makers and local communities. Additional investment in TB vaccine R&D, awareness of the need for and possibilities of new TB vaccines, and community support for vaccination are the main goals of this engagement.

Three cross-cutting enabling factors were also identified: 1) funding; 2) open science, and 3) stakeholder engagement.

TB research is underfunded globally and TB vaccine research is particularly poorly resourced. Interest in funding TB vaccine R&D needs to be increased and more funders need to be involved. Greater coordination across funders could help to increase R&D productivity and accelerate clinical evaluation. To create greater commercial interest in TB vaccine R&D, innovative funding (“push”) mechanisms need to be combined with market-shaping (“pull”) approaches, such as advance market commitments.


The Roadmap consultation identified three priority areas:1) diversifying the pipeline, 2) accelerating clinical development, and 3) ensuring public health impact.

The TB vaccine pipeline is not well-stocked and lacks diversity. Early-stage R&D has focused on a limited number of Mycobacterium tuberculosis (Mtb) antigens and on a very specific type of immune response. There is a need to:

  • Increase the diversity of the pipeline by focusing on a wider range of antigens, immune responses and delivery mechanisms.
  • Improve understanding of correlates of protection and identify biosignatures that correlate with vaccine-induced protection.
  • Improve understanding of mucosal immune responses in the lung and how they relate to systemic responses.
  • Explore the potential use of controlled human infection models.

Clinical evaluation of TB vaccines is slow, costly and high-risk. In part, this reflects the fact that efficacy in animal models is not a good predictor of efficacy in people, making it difficult to prioritise candidates for clinical evaluation. A further important barrier is the lack of well-defined correlates of protection or proxy measures of efficacy. Demonstration of efficacy therefore requires large trials with prevention of disease as the primary endpoint. There is a need to: 

  • Optimise animal models by “back-translating” findings from successful clinical trials.
  • Optimise alternative endpoints, by establishing the relationship between prevention of disease and other possible endpoints (particularly prevention of infection and prevention of recurrence).
  • Harmonising and standardising trial protocols, and exploring innovative trial designs to improve efficiency.
  • Last but not least, clinical trial capacity must be built in high-burden countries.

A key milestone in new product development is licensing approval, but this does not by itself deliver public health benefit. Multiple barriers may hamper the timely implementation of a newly licensed TB vaccine. Key challenges include limited understanding of how a new vaccine would be used within different countries, as well as the lack of investment cases to support national and global decision-making on procurement and implementation. To address these issues there is a need to:

  • Collect data to model potential impacts of vaccine use and develop country-use scenarios and investment cases
  • Undertake activities to prepare countries for evaluation of newly licensed vaccines and rapid implementation once recommended locally.
  • Identify and develop strategies to address potential barriers to implementation, including community resistance to TB vaccination.
  • Post-licensure studies should be planned to establish vaccine effectiveness.
Tuberculosis vaccine R&D roadmap

Dr Michael Makanga, EDCTP Executive Director: “The main drive for investing in this very consultative new global TB vaccine roadmap is our enduring commitment to a concerted global R&D effort that will ultimately end TB. This timely Roadmap may leverage recent advances and new opportunities arising from lessons learnt from other diseases such as COVID-19”.

The 2020 EDCTP Prize winners were announced at the Tenth EDCTP Forum: